Compass Therapeutics
Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact
A novel class of NK cell engagers overcomes CD16A deficiency
A novel class of NK cell engagers overcomes CD16A deficiency
Post navigation
Next Post
Next
CTX-471, a novel agonistic antibody targeting CD137, enhances the anti-tumor activity of tumor antigen-targeted antibodies and immune checkpoint inhibitors when used in combination
Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact